Search Results - "Enggaard L"

Current global estimates, risk factors, and knowledge gaps for Hepatitis E virus (HEV): A scoping review.

Authors: Ahmed, Md Koushik Maroofi, Hanna Blunt, Madeleine et al.

Source: PLoS Neglected Tropical Diseases. 3/11/2026, Vol. 20 Issue 3, p1-46. 46p.

Efficacy, Toxicity and Effect of Pretreatment Cardiologic Consultation on Outcomes of Ibrutinib Therapy for Chronic Lymphocytic Leukemia—A KroHem Study.

Authors: Mandac Smoljanović, Inga Aurer, Igor Bulj, Nikola et al.

Source: Cancers. Jul2025, Vol. 17 Issue 14, p2302. 15p.

How recreational therapies impact physiological and psychosocial outcomes in cancer patients: a review.

Authors: D'Oria, Marika Casà, Calogero Cenci, Cristina et al.

Source: Oncology Reviews. 2026, p1-15. 15p.

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.

Authors: Klausen U Grauslund JH Jørgensen NGD et al.

Source: Frontiers in oncology [Front Oncol] 2022 Nov 22; Vol. 12, pp. 1023015. Date of Electronic Publication: 2022 Nov 22 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Fitness in CLL.

Authors: Baratè, Claudia Scortechini, Ilaria Ciofini, Sara et al.

Source: Cancers. Jan2026, Vol. 18 Issue 2, p342. 18p.

Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences.

Authors: Coenen, Martin Bingel, Ulrike Soledad Berdaguer, Maria et al.

Source: CTS: Clinical & Translational Science. Nov2025, Vol. 18 Issue 11, p1-10. 10p.

Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers.

Authors: Piperidou, Alexia Nikolaou, Panagiota-Efstathia Fotiou, Despina

Source: International Journal of Molecular Sciences. Jun2026, Vol. 27 Issue 12, p5461. 23p.

Evidence-based investigation of the efficacy and safety of venetoclax-containing regimens versus chemoimmunotherapy in chronic lymphocytic leukemia.

Authors: Yao P Zhang J Wang X et al.

Source: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2025 Aug; Vol. 398 (8), pp. 10429-10443. Date of Electronic Publication: 2025 Feb 24.

Publication Type: Journal Article; Systematic Review; Meta-Analysis; Comparative Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.

Authors: Mauro, Francesca Romana Scalzulli, Potito Rosario Scarfò, Lydia et al.

Source: Cancers. Mar2024, Vol. 16 Issue 6, p1228. 15p.

Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.

Authors: Korsholm, Cathrine Bülow, Cille Christensen, Mikkel et al.

Source: Leukemia & Lymphoma. Feb2025, Vol. 66 Issue 2, p229-239. 11p.

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.

Authors: Kotmayer, Lili László, Tamás Mikala, Gábor et al.

Source: International Journal of Molecular Sciences. Mar2023, Vol. 24 Issue 6, p5802. 15p.

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Authors: Fürstenau M Kater AP Robrecht S et al.

Source: The Lancet. Oncology [Lancet Oncol] 2024 Jun; Vol. 25 (6), pp. 744-759.

Publication Type: Journal Article; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial; Comparative Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Real-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study.

Authors: Abrisqueta-Costa, Pau García-Marco, José Antonio Gutiérrez, Antonio et al.

Source: Cancers. Dec2024, Vol. 16 Issue 23, p4004. 15p.

Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden.

Authors: Hemminki, Kari Zitricky, Frantisek Försti, Asta et al.

Source: Cancers. Sep2024, Vol. 16 Issue 18, p3229. 12p.

Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk.

Authors: Erblich, Thomas Manisty, Charlotte Gribben, John et al.

Source: Case Reports in Hematology. 7/9/2024, Vol. 2024, p1-6. 6p.

Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course.

Authors: Angotzi, Francesco Cellini, Alessandro Ruocco, Valeria et al.

Source: Cancers. Mar2024, Vol. 16 Issue 6, p1095. 12p.

Effects of music intervention combined with progressive muscle relaxation on anxiety, depression, stress and quality of life among women with cancer receiving chemotherapy: A pilot randomized controlled trial.

Authors: Nguyen, Khanh Thi Hoang, Huong T. X. Bui, Quang V. et al.

Source: PLoS ONE. 11/3/2023, Vol. 18 Issue 11, p1-15. 15p.

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.

Authors: Burger, Jan A. Robak, Tadeusz Demirkan, Fatih et al.

Source: Leukemia & Lymphoma. Jun2022, Vol. 63 Issue 6, p1375-1386. 12p.

Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

Authors: Brieghel, Christian Galle, Veerle Agius, Rudi et al.

Source: European Journal of Haematology. May2022, Vol. 108 Issue 5, p369-378. 10p.

Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada.

Authors: Khelifi, Rania S. Huang, Steven J. Savage, Kerry J. et al.

Source: Leukemia & Lymphoma. Jun2023, Vol. 64 Issue 6, p1129-1138. 10p.